California Passes Biosimilars Bill to Promote Access to Biologic Medicines
Washington, D.C. (September 5, 2013) – Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), today issued the following statement on the California Senate's passage of Senate Bill 598:
"I commend California's Assembly and Senate for overwhelmingly passing legislation that creates a pathway for the substitution of interchangeable biologic medicines.
"As the policies outlined in Senate Bill 598 align with BIO’s principles on biologic substitution, BIO supports this important legislation and encourages Governor Brown to sign the bill when it reaches his desk.
"BIO is pleased that the California Legislature passed this legislation and continues to put patients first."